In turn, sustained CR has been reported after anti-CD33 (gentuzumab ozogamicin) in an adult MCL patient who did not respond previously to imatinib, interferon, hydroxyurea, midostaurin, and cladribine [27], and in an SM associated with the AML child who finally died from relapsing AML [26]. The gene discussed is CD33; the disease is acute myeloid leukemia.